Key Highlights
- BTAX's reported 100% move reflects a tick between $0.0001 and $0.0002, the smallest possible increment at that price.
- The company, formerly Immune Therapeutics, filed a Form 15-12G to deregister from SEC reporting in June 2026.
- Biostax filed a Form 25 delisting notice in February 2025 ahead of the full deregistration.
- Roughly 107.65 million shares are outstanding, with no current audited financials available.
On a percentage basis, a jump from $0.0001 to $0.0002 looks explosive, a clean 100% gain. In practice it is a single sub-penny tick in a stock that its own company pulled from public markets. That is the situation confronting Biostax Corp. (OTC:BTAX), a former immunotherapy developer that voluntarily Delisted and deregistered rather than a fast-moving small-cap catching a fresh bid. The eye-catching move says far more about sub-penny mechanics than about any change in the business.
Company and Latest Development
Biostax describes itself as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products, with a lead candidate, Lodonal, aimed at immune modulation in HIV/AIDS, plus assorted health-technology programs. The company, based in Winter Park, Florida and led by chief executive Noreen Griffin, was formerly known as Immune Therapeutics, Inc. and changed its name and ticker to Biostax and BTAX after FINRA approval in October 2023. The pivotal recent development is its exit from public markets: according to SEC EDGAR, Biostax (CIK 0001559356) filed a Form 25 delisting notice in February 2025 and a Form 15-12G to deregister from SEC reporting in June 2026.
What Is Driving Attention Around BTAX?
The attention stems from the arithmetic of a tiny price, not a company event. A move between $0.0001 and $0.0002 is the smallest possible increment at that price level, and it registers as a 100% change without any verifiable catalyst behind it. Because Biostax is no longer an SEC reporting company, there is limited fresh public disclosure that could explain trading, and none is identifiable. Treating the swing as a meaningful "big move" would misread how sub-penny, non-reporting securities behave.
Key Numbers and Company Position
Market data show BTAX quoted at a fraction of a cent with a market Capitalization in the tens of thousands of dollars and roughly 107.65 million shares outstanding. Its most recent Quarterly Report on file covered the period ended 30 September 2024, filed in April 2025, before the company completed its deregistration in June 2026. With SEC reporting now terminated, current, audited financials are not available, so figures on aggregators should be regarded as historical rather than up to date.
What Could Come Next?
As a deregistered issuer, Biostax is not positioned to deliver the kind of catalysts, earnings, trial data, or regulatory decisions, that move ordinary stocks through public disclosure. Any corporate development would now occur largely outside the SEC reporting framework, limiting transparency. Absent a decision to re-register or pursue a transaction, BTAX is likely to remain a dark, sub-penny quote with minimal information flow.
Risks to Watch
The risks are considerable. Deregistration removes the routine financial disclosure investors rely on, leaving little basis to value the shares. Sub-penny securities carry extreme volatility, wide spreads, and high total-loss risk, and dark or expert-market status can restrict trading access. The company's clinical programs remain early and unproven, and the large share count points to meaningful past dilution. There is no verified Revenue base to anchor the stock.
Deregistration, Not Momentum, Defines BTAX
Biostax Corp's apparent surge is a single sub-penny tick on a security the company chose to delist and deregister, not evidence of renewed momentum. The facts that matter are the 2025 delisting and the 2026 SEC deregistration. For anyone tracking BTAX, the only genuinely informative development to watch would be a return to SEC reporting or a disclosed strategic transaction.






Please wait processing your request...